Role of genetic markers in personalization of anti-angiogenic therapy in patients with exudative age-related macular degeneration

0Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

The review presents data of clinical and pharmacogenetic research by Russian and foreign authors conducted within the last three years on the effectiveness of anti-angiogenic treatment against wet age-related macular degeneration (AMD). Scientific results on the association between angiogenesis-related gene polymorphisms responsible for predisposition to AMD on the one hand and a positive response to anti-VEGF therapy on the other are presented. Particular attention is paid to the main regulator of angiogenesis – the VEGF-A gene.

Cite

CITATION STYLE

APA

Moshetova, L. K., Sychev, D. A., Osmanova, E. R., & Turkina, K. I. (2017). Role of genetic markers in personalization of anti-angiogenic therapy in patients with exudative age-related macular degeneration. Vestnik Oftalmologii. Media Sphera Publishing Group. https://doi.org/10.17116/oftalma20171336120-125

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free